Effect of gefitinib, an inhibitor of EGFR, on SCC13 cell invasion. (A) Treatment of human head and neck cutaneous squamous cell carcinoma cells with gefitinib, a small molecule inhibitor of EGFR, for 12 h inhibits invasion of cells in a concentration-dependent manner. (B) The invasive cells were counted and the results expressed as the mean number of invasive cells ± SD per microscopic field. (C) Treatment of SCC13 cells with erlotinib, an inhibitor of EGFR, inhibited cell invasion. Significant reduction of cell invasion versus untreated control cells, ¶P < 0.05, *P < 0.001. (D) Transfection of cells with EGFR-siRNA significantly decreases cell invasion. SCC13 cells were transfected with EGFR-siRNA to knockdown EGFR expression (left panel). Significant reduction of cell invasion versus control siRNA-treated cells, *P < 0.001 (right panel). (E) Western blot analysis revealed that transfection of SCC13 cells with EGFR-siRNA resulted in marked reduction in the levels of EGFR in cells.
Sun et al. BMC Complementary and Alternative Medicine 2011 11:134 doi:10.1186/1472-6882-11-134